Novartis reports positive phase 3 data on ianalumab for Sjögren’s

Novartis reported positive long-term phase 3 data for ianalumab in Sjögren’s disease, showing improved disease activity and a favorable safety profile. The FDA granted Breakthrough Therapy Designation in January, with a decision expected this year. Ianalumab is also being investigated for other autoimmune diseases. Novartis aims to address the unmet need for disease-modifying treatments in Sjögren’s.

Original reporting
Published Nov 17, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novartis reports positive phase 3 data on ianalumab for Sjögren’s — source image
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The NEPTUNUS extension data show continued deepening of systemic disease activity reductions through week 108 with a safety profile comparable to placebo, supporting the clinical case for ianalumab ahead of an FDA decision expected this year.

02

Market read

Traders may reassess ianalumab’s durability and safety profile, which can shift probability-weighted outcomes for regulatory approval in Sjögren’s.

03

What to watch

Regulatory impact depends on how these extension results map to the primary regulatory package and whether the FDA focuses on week 48 endpoints versus longer-term durability; also, the competitive context includes Amgen’s separate Phase 3 readout in the same disease.

Relevance 7/10Novelty 6/10Timing: after-hours/next-session read-through from ACR Convergence 2026 Phase 3 extension presentation

Background

Sjögren’s disease lacks an FDA-approved disease-modifying therapy, and dry eye is a hallmark feature; ianalumab targets BAFF-R to reduce B-cell driven inflammation.

Company-level read

Ticker impact

$NVSBullishMedium confidence
Context

Novartis reports positive long-term Phase 3 NEPTUNUS extension results for ianalumab in Sjögren’s, including week 108 EULAR ESSDAI reductions and safety comparable to placebo.

Expected impact

Likely modest upward bias as investors price improved efficacy durability and manageable safety, while awaiting the FDA review outcome.

Evidence & confidence

The article provides specific efficacy durability through week 108, notes no new safety signals, and reiterates FDA decision timing, which can move biotech sentiment even without an approval or guidance change.

Market effects

Reinforces competitive momentum in B-cell targeted autoimmune therapeutics for Sjögren’s, potentially raising the bar for efficacy durability and safety in the class.

Primarily impacts European large-cap biotech sentiment (Switzerland/Europe) tied to global autoimmune pipeline expectations.

Could influence global biotech risk appetite for autoimmune immunology assets as investors compare Phase 3 durability readouts across sponsors.

Counterpoint

Despite positive long-term trends, the article says no significant differences were seen at week 48 for key response endpoints and highlights injection-site/systemic reactions, which may temper enthusiasm.

Key entities

  • Novartis

    Sponsor reporting positive Phase 3 NEPTUNUS extension results for ianalumab in Sjögren’s.

  • ianalumab

    Investigational fully human monoclonal antibody targeting BAFF-R, delivered subcutaneously.

  • NEPTUNUS extension study

    Phase 3 extension presenting long-term efficacy and safety through week 108.

  • FDA

    Regulatory authority reviewing ianalumab, with a decision expected this year per the company.

Related articles

$NVSMed

FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR

The FDA approved a 150-mg dose of secukinumab (Cosentyx, Novartis) for polymyalgia rheumatica (PMR), making it the first anti-IL-17 biologic for this condition. The approval was based on the phase 3 REPLENISH trial, which showed higher remission rates with secukinumab plus a glucocorticoid taper compared to the taper alone. According to Novartis, this is the 11th US indication for secukinumab.

$NVSMed

Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial

Novartis' Cosentyx (secukinumab) 150 mg received FDA approval for polymyalgia rheumatica in patients who cannot taper steroids. The approval follows a trial where 40.5% of patients on Cosentyx achieved sustained remission at one year, compared to 20.5% on placebo. Cosentyx is the first IL-17 blocking biologic approved for this condition, according to Novartis.

$NVSMed

FDA Clears Secukinumab for Use in Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) for treating polymyalgia rheumatica (PMR) in adults unresponsive to corticosteroids. The approval follows positive phase 3 REPLENISH trial results, showing sustained remission rates of 41.2% and 40.6% for 300 mg and 150 mg doses, respectively, compared to 20.4% for placebo. Secukinumab is already approved for several other inflammatory conditions.

$NVSMed

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica (PMR) in adults with inadequate corticosteroid response. The approval follows phase 3 trial results showing sustained remission in 40.5% of patients vs. 20.5% on placebo. Secukinumab is the first IL-17 biologic approved for PMR, offering a new treatment option with a steroid-sparing effect.